OncoMatch/Clinical Trials/NCT06686771
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Is NCT06686771 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for non-small cell lung cancer.
This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cancer. The usual approach is defined as the care most people get for non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immune checkpoint inhibitor — first-line
Oligoprogression on first-line ICI +/- chemotherapy systemic therapy after at least 3 cycles.
Cannot have received: concurrent anti-cancer therapy, including investigational agents
Concurrent treatment with other anti-cancer therapy, including investigational agents.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Comprehensive Cancer Center · Duarte, California
- City of Hope at Irvine Lennar · Irvine, California
- Saint Mary's Hospital and Regional Medical Center · Grand Junction, Colorado
- Saint Luke's Cancer Institute - Boise · Boise, Idaho
- Saint Luke's Cancer Institute - Fruitland · Fruitland, Idaho
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify